Management of monoclonal lymphoproliferative disease following stem cell transplantation is difficult and previous attempts to eradicate tumor using chemotherapy or radiation therapy alone have not been successful. We report successful early eradication of an EBV negative, B cell non-Hodgkin's lymphoma in a child who received a T cell-depleted, maternal haploidentical bone marrow transplant for severe combined immunodeficiency disease. Our treatment strategy involved combining conventional induction chemotherapy with re-transplantation using the paternal donor as a source of peripheral blood 
Post-transplant lymphoproliferative disease (PTLD) is a morphologically heterogeneous group of lymphoid proliferations of varying clonal composition seen following bone marrow or solid organ transplantation. Most cases of lymphoproliferative disease are EBV driven and B cell in origin. 1 PTLD is a multistep process that begins with impaired T cell control, permitting expansion of multiple EBV infected and immortalized B cell clones. A polyclonal or oligoclonal process may respond to a decrease in immune suppression. However, monoclonal lymphoproliferations have a mortality rate of up to 90% in bone marrow transplant recipients. 2 Highly successful strategies to control EBV-associated PTLD include the use of donor leukocyte infusions or genemodified virus-specific T cells. [3] [4] [5] [6] There have been few reports of successful therapy for EBV negative PTLD in the bone marrow transplant population.
We describe a child with severe combined immunodeficiency disease (SCID) who achieved complete remission of a monoclonal PTLD following bone marrow transplantation, using a combination of chemotherapy, peripheral blood stem cell transplantation and Rituximab (IDEC Pharmaceutical Corporation, San Diego, CA, USA).
Materials and methods

EBV detection in peripheral blood
Polymerase chain reaction for the detection of latently infected peripheral blood mononuclear cells was performed on whole blood samples sent to Microbiology Reference Lab (Cypress, CA, USA) using previously described primers to a BamHI-W generated region of the EBV genome. 7 This region, IR1, is highly conserved among EBV strains and encodes a portion of the EBNA leader protein. The approximate sensitivity of this assay is 100 copies/ml of whole blood.
In situ hybridization
In situ hybridization for the detection of Epstein-Barr virus-encoded small RNAs (EBER) was performed on formalin fixed, paraffin embedded tissue using the REM-BRANDT in situ hybridization and detection kit (Kreatech Diagnostics, Amsterdam, The Netherlands).
Polymerase chain reaction
The presence of a clonal IgH heavy chain gene rearrangement was evaluated in formalin fixed, paraffin embedded tissue using one set of consensus primer pairs (FR3-A) encompassing the V and J regions of the immunoglobulin heavy chain gene, using previously established methodology. 8 
Flow cytometry
The monoclonal antibodies used in this study have been previously described. 9 Briefly, antibodies conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) were incubated for 15 min on ice with 10 5 lymph node cells per well in microtiter plates. The cells were washed twice in phosphate-buffered saline (PBS) containing 0.1% sodium azide, and the final cell pellet was suspended in 100 l of a 1:100 dilution of propidium iodide (50 g/ml; Calbiochem, La Jolla, CA, USA). Fluorescence signals were collected using four decade logarithmic amplification. Data from 10 4 cells were collected in each sample and stored in list mode.
Lysys II software (BD Immunocytometry Systems, Franklin Lakes, NJ, USA) was used for data analysis. Nonviable cells, identified by nuclear staining with propidium iodide, were excluded from analysis. Expression of the various antigens was visually assessed on bivariate plots of forward light scatter and fluorescence intensity, comparing binding of a specific antibody with that of the isotypematched IgG control. The percentage of antigen-bearing cells was calculated only when discrete positive and negative populations were observed. The flow cytometric fluorescence intensity (FI) was evaluated only with FITC-conjugated antibodies and was determined by comparing the peak of the fluorescence distribution with that of the control. If separation of positive and negative populations was not possible, the FI was defined as the peak fluorescence of the entire population. In each case, the FI of the individual antigen expression was graded, relative to the corresponding isotype-matched control, from (−) to (+++) with each exponential increase of the peak of the fluorescence distribution ((−): = negative control; (±): Ͼnegative control and р10; (+): Ͼ10 and р10 ). The assessment of immunoglobulin light chain expression was performed by analyzing light chain expression on CD19 or CD20 positive cells only.
Case report
A 3-year-old while male was diagnosed with SCID at 11 months of age after he presented with Pneumocystis carinii pneumonia and a negative HIV PCR. Immunologic evaluation revealed an IgG level of 63 mg/dl (250-690 mg/dl), and no evidence of specific antibody production to tetanus despite immunization. Although B and T cells were detected, lymphocyte proliferative responses to PHA, Con A and PWM were absent. Further testing revealed an absence of the T cell signaling protein, ZAP-70, which is a well-characterized SCID phenotype.
The child received an elutriated, T cell-depleted, haploidentical maternal bone marrow transplant at 13 months of age. Pre-transplant conditioning consisted of BU/CY/ATG followed by infusion of 1.6 × 10 6 CD34 cells/kg and 2.0 × 10 5 CD3 cells/kg. Standard GVHD prophylaxis, consisting of cyclosporine and methotrexate 5 mg/m 2 on days +1, +3, +6, and +11 was given. His post-transplant course was complicated by overall grade II acute and chronic GVHD of the skin and GI tract. The chronic skin GVHD eventually responded to tacrolimus and psoralen ultraviolet A therapy (PUVA). Six months post transplant he had 14% maternal peripheral blood cells as determined by X chromosome fluorescence in situ hybridization, and T cell proliferative capacity to all mitogens remained poor at Ͻ10% of control values.
He continued to receive monthly intravenous gammaglobulin therapy during his first year post transplant. While his serum IgG troughs remained within the normal range for a 2-year-old child (788 ± 218 mg/dl, normal 424-1051 mg/dl), his IgM and IgA levels began to climb starting 11 months post transplant. Flow cytometric analysis of the peripheral B cells revealed a marginally elevated kappa lambda ratio of 3.5 (1.5-2.9), suggesting B cell dysregulation and an evolving clonal process. An initial serum protein electrophoresis revealed a polyclonal process with no monoclonal peak.
Fourteen months post transplant, his serum IgM measured 1320 mg/dl (normal 48-168 mg/dl) with a serum IgA level of 348 mg/dl (normal 14-123 mg/dl). Serum IgG troughs continued to remain within the normal range for age while monthly infusions of intravenous gammaglobulin continued. Repeat serum protein electrophoresis at this time demonstrated a large polyclonal peak with an IgG kappa paraprotein measuring 300 mg/dl detected on immunofixation electrophoresis.
CT scan of the neck, chest, abdomen and pelvis revealed no lymphadenopathy or mass. A bone marrow aspiration and biopsy demonstrated no evidence of a lymphoproliferative process. PCR of peripheral blood lymphocytes for EBV DNA was negative. Systemic immune suppression, consisting of tacrolimus and alternate day steroids, was weaned. Two weeks following this bone marrow evaluation, he developed sudden, diffuse lymphadenopathy, evident on physical exam and CT scan (Figure 1) .
Excisional lymph node biopsy demonstrated a lymphoplasmacytic infiltrate with numerous large atypical lympho- cytes. Flow cytometric analysis of the abnormal cells revealed CD20-positive, Ig kappa restricted B cells with a high S phase fraction of 30%, consistent with a high-grade large B cell non-Hodgkin's lymphoma. Analysis of the nodal tissue for EBV was negative by in situ hybridization for EBER. PCR for immunoglobulin heavy chain gene rearrangement studies, performed on the paraffin section, confirmed the presence of a monoclonal process.
Tacrolimus was discontinued, steroids were further weaned, and he began induction chemotherapy with cyclophosphamide, adriamycin and vincristine, followed by methotrexate and ara-C. A repeat CT scan was obtained 6 weeks after the start of induction therapy, and demonstrated a partial response with a 50% reduction in tumor burden. This was followed by re-transplantation with a conditioning regimen of CY/MTX/ATG and infusion of 3.0 × 10 6 CD34-positive cells/kg and 2.2 × 10 5 CD3-positive cells/kg using paternal PBSC. A second aliquot of cells containing the same cell dose was given, 8 weeks later when detection of paternal HLA haplotype by PCR became equivocal. Stem cells were mobilized using G-CSF, and obtained by cytopheresis. CD34-positive cells were positively selected using the CellPro Ceprate SC stem cell concentration system (Cellpro Inc, Bothell, WA, USA). The patient received cyclosporine prophylaxis for GVHD.
One week following re-transplantation, the serum IgM rose precipitously from 69 mg/dl to 258 mg/dl (48-168 mg/dl). Since a polyclonal elevation in IgM had been the initial surrogate marker of B cell dysregulation in this patient, we elected to begin additional anti-B cell therapy. On day +8, Rituximab was started at a dose of 375 mg/m 2 weekly for 4 weeks.
Results
Ten weeks following re-transplantation and 5 months from initial diagnosis of PTLD, a CT scan showed no evidence of residual tumor (Figure 2 ). Serum IgM levels became undetectable, and flow cytometric analysis of PBMC demonstrated no CD20-positive B cells. The patient experienced transient grade 1 acute GVHD of the skin, not con- Bone Marrow Transplantation firmed by biopsy, that required no additional therapy. Six months following transplant, he developed Stevens-Johnson syndrome temporally related to an acute viral syndrome. Following resolution of this, he required additional corticosteroid therapy for a biopsy documented flare in cutaneous GVHD that has since resolved. Neutrophil engraftment occurred on day +11 and the patient has remained transfusion independent. PCR for EBV DNA in the peripheral blood has remained negative. Non-quantitative PCR 5 months post-transplant demonstrated the presence of paternal donor HLA haplotype in the recipient's peripheral blood mononuclear cells. The patient remains clinically well with a normal serum protein electrophoresis and no evidence of lymphadenopathy or hypergammaglobulinemia 12 months post transplant. T cell proliferation to PHA and PWM is 70% of control values a year post transplant. CD20-positive cells were detectable in the periphery 6 months after the completion of Rituximab. Serum IgM was measurable at 8 months and normalized at 10 months following anti-CD20 monoclonal antibody therapy. The patient is still receiving intravenous gammaglobulin replacement therapy, which is being slowly weaned.
Discussion
The frequency of PTLD varies according to the type of bone marrow transplant with the highest rates of disease reported for T-depleted, HLA mismatched transplants. 10 The majority of transplants for SCID have been performed using parental haploidentical donors employing some form of T depletion, placing these children in the highest risk category for PTLD. 11 Children with SCID are also at increased risk for malignancy pre-transplant, emphasizing the key role of cellular immunity in tumor surveillance. For patients with severe T cell dysfunction, either as a result of underlying primary immunodeficiency disease, or secondary immunodeficiency due to immunosuppressive drugs, poor graft function, or GVHD, strategies that incorporate restoration of anti-viral or anti-tumor CTL activity are critical to the success of therapy. Our patient tolerated initial conventional induction chemotherapy for this rapidly proliferating B cell lymphoma. Neutrophil recovery was delayed by approximately 2 weeks despite the use of G-CSF, but the child experienced no documented infections during that time.
The alternate parental donor was chosen as a source of stem cells for re-transplantation in this case for two reasons. Chronic graft-versus-host disease had been particularly problematic with the maternal graft, and precluded the administration of additional maternal cells despite the fact that the graft was poorly functional. In addition, we were not able to determine whether the tumor was of maternal donor or recipient origin. Peripheral blood stem cells were chosen as the source of CD34-positive cells in case additional infusions of donor lymphocytes were required to provide adoptive immunotherapy for tumor control.
Murine and humanized monoclonal anti-B cell antibodies have been used with some success in the treatment of PTLD. [12] [13] [14] Rituximab (Rituxan) is a chimeric humanized monoclonal antibody recently approved for the treatment of low-grade B cell non-Hodgkin's lymphoma. It binds to CD20, a cell surface protein expressed on all B cells from the early pre-B to mature B cell stage of differentiation. It is not expressed on pluripotent stem cells, pro-B cells or plasma cells. 15 The rationale for using Rituximab in B cell PTLD rests with its ability to effectively deplete B cells without affecting the stem cell compartment. Thus, the target cell for malignant transformation may be temporarily eliminated, until T cell function is restored post-transplant.
Administration of Rituximab had been considered prior to the development of full-blown PTLD in this case. However, at the time this patient presented with an evolving clonal process, Rituximab had not been given to any child under the age of 3 years, and there was no literature to support the use of prophylactic infusions of anti-CD20 monoclonal antibody. In addition, although administration of Rituximab alone may have temporized the evolution of lymphoproliferative disease in this case, it would not have solved the underlying problem of abnormal immune function. We extrapolated our infusion protocol based on an average adult's weight. This child tolerated an initial infusion rate of 1 mg/kg/hour titrated upward every 30 min to a maximum of 4 mg/kg/h. He received diphenhydramine and acetaminophen premedication prior to the infusion, and experienced no infusion-related problems.
This three-pronged approach for the control of non-EBVdriven PTLD following stem cell transplantation has the advantage of addressing several phases in tumor control in the immune deficient host. Conventional induction chemotherapy serves to rapidly decrease the initial tumor burden. This is followed by stem cell transplantation as a consolidation therapy that also has the capability to restore normal immunity, and provide small numbers of mature T lymphocytes for their potential graft-versus-tumor effect. Finally, since restoration of normal immunity is delayed for up to 2 years following bone marrow transplantation, 16 temporary elimination of any residual abnormal B cells using anti-CD20 monoclonal antibody is an attractive option.
Close follow-up will be needed to assess the durability of this remission and any long-term effects on B cell reconstitution. The combination of induction chemotherapy followed by stem cell transplantation and anti-B cell therapy was well tolerated in this patient, and achieved an early, complete remission of EBV negative monoclonal PTLD.
